TQ-B3395

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameTQ-B3395
Drug Alias NameTQ-B-3395TQ-B3395CT-1495
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungBreast NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co LtdBeijing Centaurus Biopharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShouyao Holding (Beijing) Co LtdJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesBeijing Centaurus Biopharma Co Ltd
Active IndicationsCarcinoma, Non-Small-Cell LungBreast Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A